Theravance Short Long Term Debt Total from 2010 to 2024
| TBPH Stock | USD 9.47 0.14 1.46% |
Short and Long Term Debt Total | First Reported 2016-12-31 | Previous Quarter 46.7 M | Current Value 45 M | Quarterly Volatility 253.3 M |
Check Theravance Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theravance Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 2.2 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 3.06. Theravance financial statements analysis is a perfect complement when working with Theravance Biopharma Valuation or Volatility modules.
Theravance | Short Long Term Debt Total |
Latest Theravance Biopharma's Short Long Term Debt Total Growth Pattern
Below is the plot of the Short Long Term Debt Total of Theravance Biopharma over the last few years. It is Theravance Biopharma's Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theravance Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Short Long Term Debt Total | 10 Years Trend |
|
Short Long Term Debt Total |
| Timeline |
Theravance Short Long Term Debt Total Regression Statistics
| Arithmetic Mean | 279,923,937 | |
| Geometric Mean | 215,104,777 | |
| Coefficient Of Variation | 69.19 | |
| Mean Deviation | 150,227,100 | |
| Median | 222,676,000 | |
| Standard Deviation | 193,680,538 | |
| Sample Variance | 37512.2T | |
| Range | 605.4M | |
| R-Value | 0.06 | |
| Mean Square Error | 40244.3T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | 2,668,551 | |
| Total Sum of Squares | 525170.1T |
Theravance Short Long Term Debt Total History
About Theravance Biopharma Financial Statements
Investors use fundamental indicators, such as Theravance Biopharma's Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although Theravance Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 49.2 M | 46.7 M |
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out the analysis of Theravance Biopharma Correlation against competitors. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.